Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery

Eli Gilboa, Alexey Berezhnoy, Brett Schrand

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune therapies. A general way to reduce toxicity is to target immune potentiating drugs to the tumor or immune cells of the patient. This Crossroads article discusses a new class of nucleic acidbased immune-modulatory drugs that are targeted to the tumor or to the immune system by conjugation to oligonucleotide aptamer ligands. Cell-free chemically synthesized short oligonucleotide aptamers represent a novel and emerging platform technology for generating ligands with desired specificity that offer exceptional versatility and feasibility in terms of development, manufacture, and conjugation to an oligonucleotide cargo. In proof-of-concept studies, aptamer ligands were used to target immune-modulatory siRNAs or aptamers to induce neoantigens in the tumor cells, limit costimulation to the tumor lesion, or enhance the persistence of vaccine-induced immunity. Using increasingly relevant murine models, the aptamer-targeted immune-modulatory drugs engendered protective antitumor immunity that was superior to that of current "gold-standard" therapies in terms of efficacy and lack of toxicity or reduced toxicity. To overcome immune exhaustion aptamer-targeted siRNA conjugates could be used to downregulate intracellular mediators of exhaustion that integrate signals from multiple inhibitory receptors. Recent advances in aptamer development and second-generation aptamerdrug conjugates suggest that we have only scratched the surface.

Original languageEnglish (US)
Pages (from-to)1195-1200
Number of pages6
JournalCancer immunology research
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Oligonucleotides
Pharmaceutical Preparations
Neoplasms
Ligands
Immunity
Therapeutics
Protective Agents
Gold
Immunotherapy
Small Interfering RNA
Immune System
Down-Regulation
Vaccines
Technology
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Immunology

Cite this

Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery. / Gilboa, Eli; Berezhnoy, Alexey; Schrand, Brett.

In: Cancer immunology research, Vol. 3, No. 11, 01.11.2015, p. 1195-1200.

Research output: Contribution to journalArticle

@article{bb05aae471384d399f47585dabf9a12b,
title = "Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery",
abstract = "Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune therapies. A general way to reduce toxicity is to target immune potentiating drugs to the tumor or immune cells of the patient. This Crossroads article discusses a new class of nucleic acidbased immune-modulatory drugs that are targeted to the tumor or to the immune system by conjugation to oligonucleotide aptamer ligands. Cell-free chemically synthesized short oligonucleotide aptamers represent a novel and emerging platform technology for generating ligands with desired specificity that offer exceptional versatility and feasibility in terms of development, manufacture, and conjugation to an oligonucleotide cargo. In proof-of-concept studies, aptamer ligands were used to target immune-modulatory siRNAs or aptamers to induce neoantigens in the tumor cells, limit costimulation to the tumor lesion, or enhance the persistence of vaccine-induced immunity. Using increasingly relevant murine models, the aptamer-targeted immune-modulatory drugs engendered protective antitumor immunity that was superior to that of current {"}gold-standard{"} therapies in terms of efficacy and lack of toxicity or reduced toxicity. To overcome immune exhaustion aptamer-targeted siRNA conjugates could be used to downregulate intracellular mediators of exhaustion that integrate signals from multiple inhibitory receptors. Recent advances in aptamer development and second-generation aptamerdrug conjugates suggest that we have only scratched the surface.",
author = "Eli Gilboa and Alexey Berezhnoy and Brett Schrand",
year = "2015",
month = "11",
day = "1",
doi = "10.1158/2326-6066.CIR-15-0194",
language = "English (US)",
volume = "3",
pages = "1195--1200",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery

AU - Gilboa, Eli

AU - Berezhnoy, Alexey

AU - Schrand, Brett

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune therapies. A general way to reduce toxicity is to target immune potentiating drugs to the tumor or immune cells of the patient. This Crossroads article discusses a new class of nucleic acidbased immune-modulatory drugs that are targeted to the tumor or to the immune system by conjugation to oligonucleotide aptamer ligands. Cell-free chemically synthesized short oligonucleotide aptamers represent a novel and emerging platform technology for generating ligands with desired specificity that offer exceptional versatility and feasibility in terms of development, manufacture, and conjugation to an oligonucleotide cargo. In proof-of-concept studies, aptamer ligands were used to target immune-modulatory siRNAs or aptamers to induce neoantigens in the tumor cells, limit costimulation to the tumor lesion, or enhance the persistence of vaccine-induced immunity. Using increasingly relevant murine models, the aptamer-targeted immune-modulatory drugs engendered protective antitumor immunity that was superior to that of current "gold-standard" therapies in terms of efficacy and lack of toxicity or reduced toxicity. To overcome immune exhaustion aptamer-targeted siRNA conjugates could be used to downregulate intracellular mediators of exhaustion that integrate signals from multiple inhibitory receptors. Recent advances in aptamer development and second-generation aptamerdrug conjugates suggest that we have only scratched the surface.

AB - Modulating the function of immune receptors with antibodies is ushering in a new era in cancer immunotherapy. With the notable exception of PD-1 blockade used as monotherapy, immune modulation can be associated with significant toxicities that are expected to escalate with the development of increasingly potent immune therapies. A general way to reduce toxicity is to target immune potentiating drugs to the tumor or immune cells of the patient. This Crossroads article discusses a new class of nucleic acidbased immune-modulatory drugs that are targeted to the tumor or to the immune system by conjugation to oligonucleotide aptamer ligands. Cell-free chemically synthesized short oligonucleotide aptamers represent a novel and emerging platform technology for generating ligands with desired specificity that offer exceptional versatility and feasibility in terms of development, manufacture, and conjugation to an oligonucleotide cargo. In proof-of-concept studies, aptamer ligands were used to target immune-modulatory siRNAs or aptamers to induce neoantigens in the tumor cells, limit costimulation to the tumor lesion, or enhance the persistence of vaccine-induced immunity. Using increasingly relevant murine models, the aptamer-targeted immune-modulatory drugs engendered protective antitumor immunity that was superior to that of current "gold-standard" therapies in terms of efficacy and lack of toxicity or reduced toxicity. To overcome immune exhaustion aptamer-targeted siRNA conjugates could be used to downregulate intracellular mediators of exhaustion that integrate signals from multiple inhibitory receptors. Recent advances in aptamer development and second-generation aptamerdrug conjugates suggest that we have only scratched the surface.

UR - http://www.scopus.com/inward/record.url?scp=84957542643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957542643&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-15-0194

DO - 10.1158/2326-6066.CIR-15-0194

M3 - Article

C2 - 26541880

AN - SCOPUS:84957542643

VL - 3

SP - 1195

EP - 1200

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 11

ER -